Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc.Rupert Hargreaves
According to a report published by Bloomberg this morning, Baxalta Inc. has abandoned its pursuit of Ariad Pharmaceuticals Inc. The report suggests that the deal broke down earlier this week, due to a disagreement over the price Baxalta was willing to pay for its smaller peer.
Shares of Ariad, which develops leukemia and lung cancer treatments, fell as much as 22% in . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat